Corcept Therapeutics (CORT) Competitors $52.42 -2.72 (-4.93%) (As of 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CORT vs. RPRX, JAZZ, PRGO, SUPN, PCRX, OMER, NKTR, ASMB, CPIX, and LLYShould you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry. Corcept Therapeutics vs. Royalty Pharma Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Omeros Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations. Does the MarketBeat Community prefer RPRX or CORT? Corcept Therapeutics received 215 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.16% of users gave Corcept Therapeutics an outperform vote while only 67.86% of users gave Royalty Pharma an outperform vote. CompanyUnderperformOutperformRoyalty PharmaOutperform Votes32367.86% Underperform Votes15332.14% Corcept TherapeuticsOutperform Votes53871.16% Underperform Votes21828.84% Do analysts rate RPRX or CORT? Royalty Pharma currently has a consensus price target of $41.67, suggesting a potential upside of 70.28%. Corcept Therapeutics has a consensus price target of $65.25, suggesting a potential upside of 24.48%. Given Royalty Pharma's higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than Corcept Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Royalty Pharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, RPRX or CORT? Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoyalty Pharma$2.27B6.36$1.13B$1.9312.68Corcept Therapeutics$628.56M8.74$106.14M$1.2641.60 Do institutionals & insiders believe in RPRX or CORT? 54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 18.9% of Royalty Pharma shares are held by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, RPRX or CORT? Royalty Pharma has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Is RPRX or CORT more profitable? Royalty Pharma has a net margin of 50.53% compared to Corcept Therapeutics' net margin of 22.35%. Royalty Pharma's return on equity of 24.65% beat Corcept Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Royalty Pharma50.53% 24.65% 14.44% Corcept Therapeutics 22.35%24.54%20.24% Does the media favor RPRX or CORT? In the previous week, Corcept Therapeutics had 11 more articles in the media than Royalty Pharma. MarketBeat recorded 19 mentions for Corcept Therapeutics and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.73 beat Corcept Therapeutics' score of 0.54 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Corcept Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCorcept Therapeutics beats Royalty Pharma on 10 of the 17 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORT vs. The Competition Export to ExcelMetricCorcept TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.49B$6.72B$5.03B$8.96BDividend YieldN/A3.07%4.83%4.06%P/E Ratio41.6010.45133.4516.94Price / Sales8.74187.591,120.44116.28Price / Cash62.7357.1640.6337.95Price / Book10.655.194.754.71Net Income$106.14M$151.85M$118.34M$225.20M7 Day Performance-12.75%-7.93%11.87%-3.77%1 Month Performance-0.38%-1.49%11.93%4.45%1 Year Performance71.64%12.16%31.39%18.66% Corcept Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORTCorcept Therapeutics4.6675 of 5 stars$52.42-4.9%$65.25+24.5%+85.3%$5.49B$628.56M41.60300Short Interest ↓RPRXRoyalty Pharma4.6867 of 5 stars$25.11+1.1%$41.67+65.9%-8.2%$14.79B$2.36B12.8780JAZZJazz Pharmaceuticals4.8692 of 5 stars$125.01+1.6%$177.00+41.6%+0.8%$7.56B$3.99B17.332,800PRGOPerrigo4.9777 of 5 stars$27.13-1.2%$37.00+36.4%-9.7%$3.70B$4.66B-23.469,140SUPNSupernus Pharmaceuticals2.5031 of 5 stars$36.62+1.2%$36.00-1.7%+32.9%$2.02B$651.97M33.91580PCRXPacira BioSciences3.8118 of 5 stars$20.17+1.6%$23.50+16.5%-36.6%$931.25M$674.98M-9.78720Analyst RevisionOMEROmeros3.4461 of 5 stars$7.76+1.7%$9.00+16.0%+177.5%$449.69MN/A0.00198Positive NewsNKTRNektar Therapeutics4.4882 of 5 stars$1.03+1.5%$4.10+300.0%+117.7%$189.07M$93.14M-1.20220ASMBAssembly Biosciences4.0783 of 5 stars$15.50+0.8%$35.00+125.8%+58.1%$98.52M$28.33M0.00100Gap UpCPIXCumberland Pharmaceuticals0.4721 of 5 stars$2.17-8.8%N/A+19.8%$30.47M$36.79M-2.8380Gap UpLLYEli Lilly and Company4.9958 of 5 stars$779.75-1.2%$1,002.22+28.5%+36.1%$740.23B$40.86B85.4843,000Buyback Announcement Related Companies and Tools Related Companies Royalty Pharma Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Omeros Competitors Nektar Therapeutics Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CORT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CORT Stock Alerts